Pucotenlimab clinical trials
Pucotenlimab is named as an intervention in 36 current clinical trials in our China, Japan and France registers. 22 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Sun Yat-sen University (10). The most-studied condition is Penile Cancer.
How Pucotenlimab works
All drug targets →- Programmed cell death protein 1 inhibitor InhibitorTarget: PDCD1 programmed cell death 1✓ In ChEMBL and the Guide to Pharmacology
- Colorectal cancerPhase 3
- Gastric adenocarcinomaPhase 3
- Gastroesophageal junction adenocarcinomaPhase 3
- MelanomaPhase 3
- Nasopharyngeal carcinomaPhase 3
- Rectal cancerPhase 3
- Biliary tract cancerPhase 2/3
- Non-small cell lung carcinomaPhase 2/3
- Acral lentiginous melanomaPhase 2
- Breast cancerPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4650472, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 13886, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Pucotenlimab
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Pucotenlimab
36 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Pucotenlimab
44 conditionsAll 44 conditions
| Condition (as registered) | Trials |
|---|---|
| Penile Cancer | 4 |
| Metastatic Colorectal Cancer | 2 |
| Head and Neck Cancer | 2 |
| Head and Neck Squamous Cell Carcinoma | 2 |
| Rhabdomyosarcoma | 1 |
| Pediatric Cancer | 1 |
| Recurrent or Metastatic Nasopharyngeal Carcinoma | 1 |
| Cancer of Unknown Primary | 1 |
| Salivary Gland Carcinomas | 1 |
| Rectal Cancer | 1 |
| Melanoma Metastatic | 1 |
| NRAS Mutation | 1 |
| Cutaneous Squamous Cell Carcinoma (CSCC) | 1 |
| Advanced Refractory Solid Tumors | 1 |
| EGFR Gene Overexpression | 1 |
| Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | 1 |
| Lymphoepithelioma-like Carcinoma | 1 |
| Lymphoepithelioma | 1 |
| Carcinoma | 1 |
| Squamous Cell Carcinoma of Head and Neck | 1 |
| Squamous Cell Carcinoma of Head and Neck (SCCHN) | 1 |
| NSCLC (Advanced Non-small Cell Lung Cancer) | 1 |
| Pancreatic Cancer | 1 |
| PD-L1 | 1 |
| PD-1 Inhibitor | 1 |
| LDRT | 1 |
| Thyroid Cancer | 1 |
| Colorectal Cancer (CRC) | 1 |
| Gastric (Stomach) Cancer | 1 |
| Rectal Adenocarcinoma | 1 |
| LA HNSCC | 1 |
| Oral Squamous Cell Carcinoma | 1 |
| Locally Advanced Head and Neck Cancer | 1 |
| Neoadjuvant Therapy | 1 |
| Hepatocellular Carcinoma | 1 |
| Intrahepatic Cholangiocarcinoma (Icc) | 1 |
| Hepatic Arterial Infusion Chemotherapy | 1 |
| Cholangiocarcinoma Non-resectable | 1 |
| Penile Squamous Cell Carcinoma (PSCC) | 1 |
| Locally Advanced Head and Neck Squamous Cell Carcinoma | 1 |
| Solid Tumor | 1 |
| Gastrointestinal Cancer | 1 |
| Advanced Solid Tumors | 1 |
| Melanoma | 1 |
Sponsors
lead sponsor per trial+ 3 more sponsors in the trial list above.
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 35 | 21 |
| Clinical trials in Japan | 1 | 0 |
| Clinical trials in France | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Pucotenlimab trials
How many clinical trials are testing Pucotenlimab?
36 current trials in our China, Japan and France registers name Pucotenlimab (also registered as HX008) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Pucotenlimab trials recruiting patients?
Yes. 22 of the 36 trials are recruiting: 21 with sites in China and 1 with sites in France. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Pucotenlimab clinical trials?
Sun Yat-sen University (10), Lepu Biopharma Co., Ltd (4), Fudan University (4) and Sir Run Run Shaw Hospital (2), among 18 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Pucotenlimab works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Pucotenlimab works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Pucotenlimab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.